Mineralocorticoid receptor blockade but not steroid withdrawal reverses renal fibrosis in deoxycorticosterone/salt rats

Endocrinology

Volumn 147, Issue 7, 2006, Pages 3623-3629

  Lam, Emily Y M ^a   Funder, John W ^a   Nikolic Paterson, David J ^b   Fuller, Peter J ^a   Young, Morag J ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CYCLOOXYGENASE 2; DEOXYCORTICOSTERONE; EPLERENONE; MINERALOCORTICOID RECEPTOR; OSTEOPONTIN; RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE; STEROID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FOOD; KIDNEY FIBROSIS; KIDNEY PARENCHYMA; KIDNEY TUBULE DISORDER; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; RENAL PROTECTION; TISSUE INJURY;

ANIMALS; COLLAGEN; CYCLOOXYGENASE 2; DESOXYCORTICOSTERONE; FIBROSIS; HEME OXYGENASE-1; INFLAMMATION; KIDNEY; MALE; OSTEOPONTIN; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; SIALOGLYCOPROTEINS; STEROIDS;

EID: 33745174906     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2005-1527     Document Type: Article

References (35)

1. Fuller PJ, Young MJ 2005 Mechanisms of mineralocorticoid action. Hypertension 46:1227-1235
2. Young M, Fullerton M, Dilley R, Funder J 1994 Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 93:2578-2583
3. Young M, Head G, Funder J 1995 Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 269:E657-E662
4. Young MJ, Moussa L, Dilley R, Funder JW 2003 Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11β-hydroxysteroid dehydrogenase inactivation. Endocrinology 144:1121-1125
5. Rocha R, Chander PN, Zuckerman A, Stier Jr CT 1999 Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33:232-237
6. Brilla CG, Weber KT 1992 Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120:893-901
7. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG 2003 Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63:1791-1800
8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717
9. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatin M, and the Eplerenone Post-Acute Myocardial Infarction Heart Failure, Efficacy Survival Study Investigators 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med [Erratum (2003) 348:2271] 348:1309-1321
10. Epstein M 2003 Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant 18:1984-1992
11. Hollenberg NK 2004 Aldosterone in the development and progression of renal injury. Kidney Int 66:1-9
12. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, Roniker B, Patrick JL, Krause SL 2004 Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 93:990-996
13. Rocha R, Stier Jr CT, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK 2000 Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141:3871-3878
14. Nikolic-Paterson DJ, Atkins RC 2001 The role of macrophages in glomerulonephritis. Nephrol Dial Transplant 16:3-7
15. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollins BJ, Tesch GH 2006 Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69:73-80
16. Ikezum Y, Hurst LA, Masaki T, Atkins RC, Nikolic-Paterson DJ 2003 Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. Kidney Int 63:83-95
17. Young MJ, Funder JW 2004 Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 145:3153-3157
18. Rocha R, Rudolph AE, Frierdich GE, Nochowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA 2002 Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283:H1802-H1810
19. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL 2004 Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 43:1252-1257
20. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E 2002 Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143:4828-4836
21. Trachtman H, Weiser AC, Valderrama E, Morgado M, Palmer LS 2004 Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J Urol 172:1590-1594
22. Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TN, Salant DJ, Gutierrez-Ramos JC 1997 RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 185:1371-1380
23. Rovin BH, Doe N, Tan LC 1996 Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis 27:640-646
24. Yu XQ, Nikolic-Paterson DJ, Mu W, Giachelli CM, Atkins RC, Johnson RJ, Lan HY 1998 A functional role for osteopontin in experimental crescentic glomerulonephritis in the rat. Proc Assoc Am Physicians 110:50-64
25. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R, Iredale JP 2005 Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115:56-65
26. Cheng HF, Harris RC 2005 Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des 11:1795-1804
27. Krotz F, Schiele TM, Klauss V, Sohn HY 2005 Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 42:312-324
28. Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL 2004 Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotensin system. Am J Hypertens 17:597-603
29. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M 2004 Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin- converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109:2213-2220
30. Nishiyama A, Abe Y 2004 Aldosterone and renal injury. Nippon Yakurigaku Zasshi 124:101-109
31. Funder JW, Pearce PT, Smith R, Smith AI 1988 Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583-585
32. Myles K, Funder JW 1996 Progesterone binding to mineralocorticoid receptors: in vitro and in vivo studies. Am J Physiol 270:E601-E607
33. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A 2001 Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104:467-472
34. Funder JW 2005 RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93:121-125
35. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH 2003 Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108:1831-1838